Targeted Protein Degraders Market - Global Forecast To 2035
商品番号 : SMB-85317
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 354 |
| 図表数 | 539 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、標的タンパク質分解市場を、タイプ別（分子接着剤（メジグドミド、イベルドミド）、SERD（エラセストラント、ジレデストラント、カミゼストラント）、PROTAC（ベプデゲストラント、バブデガルタミド、BGB-16673、NX-5948、KT-474）、LDD/BiDAC、LYTAC/ATAC、オートファジー標的キメラ）、治療適応症別（腫瘍学、炎症性疾患など）、製剤別（経口製剤および注射剤）、エンドユーザー別（病院および専門クリニック、長期ケア施設および在宅ケア環境）、地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）に分類しています。
本レポートは、標的タンパク質分解市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。標的タンパク質分解市場に関連する新規承認／発売、提携、買収、および最近の動向についても取り上げています。
世界の標的タンパク質分解市場は、2025年の推定4億8,000万米ドルから2035年には98億5,000万米ドルに達し、2025年から2035年にかけて年平均成長率（CAGR）35.4%で成長すると予測されています。標的タンパク質分解市場の拡大は、主に資本流入、大手製薬企業との提携、そして複数の適応症への拡大によって牽引されてきました。しかしながら、ヘテロ二機能性化合物のCMC（医薬品製造管理）およびスケールアップの複雑さ、そして知的財産権をめぐる紛争が市場の成長を抑制すると予想されます。
The global targeted protein degradation market is projected to reach USD 9.85 billion by 2035 from an estimated USD 0.48 billion in 2025, at a CAGR of 35.4% from 2025 to 2035. The expansion of the targeted protein degradation market has been predominantly fueled by Capital inflows & big-pharma tie-ups, and multi-indication expansion. However, CMC & scale-up complexity for heterobifunctional and IP disputes are expected to restrain market growth.
The oncology segment reported the highest CAGR in the therapeutic indications segment in 2024.
Based on therapeutic indications, the market is categorized into oncology, inflammatory diseases, and other therapeutic indications. Oncology is projected to exhibit the highest CAGR in the targeted protein degradation Market among all therapeutic indication segments. This rapid growth is driven by the increasing global burden of cancer and the urgent need for therapies that can target disease-causing proteins once considered undruggable. TPD technologies, including PROTACs and molecular glue degraders, offer a revolutionary approach by degrading, rather than inhibiting key oncogenic proteins, leading to more complete and durable therapeutic responses. Several biotech and pharmaceutical companies are advancing TPD candidates specifically for oncology indications, including prostate, breast, lung, hematologic, and solid tumors. Industry leaders, such as Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, are developing clinical-stage degraders targeting critical cancer-related proteins like AR, ER, STAT3, and BTK. Additionally, big pharma partnerships and increasing regulatory support are accelerating development timelines.
With a growing focus on precision medicine, rising cancer incidence, and limitations of existing therapies, the oncology segment is poised to dominate the targeted protein degradation market. Continued innovation in TPD design, biomarker integration, and combination therapies will further drive growth and solidify oncology’s role as the most dynamic and promising application area in this market.
The homecare settings segment registered the highest CAGR in the targeted protein degradation market by end user.
The targeted protein degradation market is segmented by end users into hospitals & specialty clinics, long-term care facilities, and home care settings. In 2024, the home care settings segment emerged as the fastest-growing end-user segment in the targeted protein degraders (TPD) market, driven by the growing demand for patient-centric, convenient, and cost-effective treatment options. One of the key factors contributing to this trend is the increasing development of oral TPD formulations, which allow patients to manage complex conditions like cancer and autoimmune diseases from the comfort of their homes. Unlike traditional biologics requiring hospital administration, oral degraders enable safe, effective treatment without the need for frequent clinic visits, significantly improving patient compliance and quality of life. The shift toward home-based care is further supported by the integration of digital health technologies, including remote patient monitoring and telehealth platforms, which allow physicians to track treatment response and manage side effects in real time. Healthcare systems are actively encouraging homecare models to reduce hospital burden and control treatment costs. As more targeted protein degraders progress through late-stage clinical development and gain regulatory approval, the dominance of home care settings is expected to strengthen. With their convenience, scalability, and alignment with modern healthcare delivery models, home care environments represent a vital and expanding channel for TPD therapies in the evolving treatment landscape.
North America accounted for the largest share in the global targeted protein degradation market from 2025 to 2030.
North America accounted for the largest share in the targeted protein degradation market, driven by a strong foundation in biotechnology innovation, a favorable regulatory landscape, and significant investment activity. The region is home to several pioneering TPD companies, including Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, which are advancing cutting-edge degrader technologies into clinical development. In addition, major pharmaceutical firms such as Bristol Myers Squibb and Pfizer are actively expanding their TPD pipelines through collaborations and internal R&D. The region benefits from a mature healthcare infrastructure, access to top-tier academic research institutions, and early adoption of novel therapeutic modalities. The US Food and Drug Administration (FDA) has shown increasing recognition of TPD-based therapies, granting designations that facilitate faster development and approval. Furthermore, the growing emphasis on oral and home-based treatments aligns well with healthcare delivery models in North America.
These factors collectively position North America as a key driver of innovation, commercialization, and clinical advancement in the global TPD market, making it the fastest-growing regional segment.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side- 30%
- By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
- By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%
Key Companies
Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer (Vividion) (Germany), Captor Therapeutics (Poland), Ranok Therapeutics (US), Pfizer (US), Novartis (Switzerland), and Foghorn Therapeutics (US).
Research Coverage
This research report categorizes the targeted protein degradation market, by type [molecular glue (mezigdomide, Iberdomide), SERDs (Elacestrant, Giredestrant, Camizestrant), PROTAC (Vepdegestrant, Bavdegalutamide, BGB-16673, NX-5948, KT-474), LDD/BiDAC, LYTAC/ATAC, Autophhagy-targeting chimeras] therapeutic indication (oncology, inflammatory diseases, and others), Formulation (oral formulationsand injections), end user (hospitals & speciality clinics, long-term care facility and home care settings) and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the targeted protein degradation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the targeted protein degradation market.
Reasons to buy this report
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall targeted protein degradation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing first-In-class approvals with priority/FT designations, expanding multi-indication use, increasing capital inflows and big-pharma collaborations, and technological advancements in degrader design and discovery) restraints (CMC and scale-up complexity for heterobifunctionals, off-target toxicity and cytokine storms in first-gen PROTACs, and IP disputes), opportunities (Growing adoption of CNS and immunology degraders in clinics, development of next-gen ligases with tissue-selective expression, and increasing NDA filing for innovative degraders), and challenges (Limited ligase expression and strict regulatory guidelines) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the targeted protein degradation market
- Market Development: Comprehensive information about lucrative markets across varied regions
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the targeted protein degradation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the targeted protein degradation market.
Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 37
1.3.2 INCLUSIONS AND EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Objectives of secondary research 41
2.1.1.2 Key data from secondary sources 42
2.1.2 PRIMARY DATA 42
2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 43
2.1.2.2 Key objectives of primary research 43
2.2 MARKET SIZE ESTIMATION 44
2.2.1 GLOBAL MARKET SIZE ESTIMATION 44
2.2.1.1 Company revenue analysis (Bottom-up approach) 44
2.2.1.2 Revenue share analysis 45
2.2.1.3 MnM repository analysis 46
2.2.1.4 Primary interviews 46
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 47
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 47
2.3 GROWTH RATE PROJECTIONS 49
2.4 DATA TRIANGULATION 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 RESEARCH LIMITATIONS 52
2.7 RISK ANALYSIS 52
3 EXECUTIVE SUMMARY 53
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 53
3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES 53
3.1.2 ESTABLISHED MARKET LEADERS 53
3.1.3 CDMOS AND CROS 54
4 PREMIUM INSIGHTS 59
4.1 NOVEL TARGETED PROTEIN DEGRADERS MARKET OVERVIEW 59
4.2 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE AND COUNTRY, 2030 60
4.3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
4.4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: EMERGING VS.
DEVELOPED MARKETS 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
5.2.1 DRIVERS 65
5.2.1.1 Growing approvals and favorable regulatory environment 65
5.2.1.2 Multi-indication expansion 65
5.2.1.3 Capital inflows and big pharma tie-ups 66
5.2.1.4 Technological advancements in design and discovery 67
5.2.2 RESTRAINTS 67
5.2.2.1 Cost and scalability issues 67
5.2.2.2 Safety-related concerns 68
5.2.2.3 Intellectual property disputes 69
5.2.3 OPPORTUNITIES 69
5.2.3.1 Advancements in medicinal chemistry 69
5.2.3.2 Development of next-gen ligases with tissue-selective expressions 70
5.2.3.3 Increasing NDA filings for innovative degraders 70
5.2.4 CHALLENGES 71
5.2.4.1 Limited ligase expression in tissues 71
5.2.4.2 Strict regulatory guidelines 71
5.3 TECHNOLOGY ANALYSIS 72
5.3.1 KEY TECHNOLOGIES 72
5.3.1.1 PROTACS (hetero-bifunctional) 72
5.3.1.2 Molecular glues/CELMODS 72
5.3.2 COMPLEMENTARY TECHNOLOGIES 73
5.3.2.1 Next-gen E3-ligase binder discovery 73
5.3.2.2 Nanoparticle/LNP delivery of degraders 73
5.3.3 ADJACENT TECHNOLOGIES 73
5.3.3.1 Antibody-drug conjugates (ADCs) 73
5.3.3.2 GENE editing/siRNA 73
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 74
5.5 PRICING ANALYSIS 75
5.5.1 QUALITATIVE PRICING INSIGHTS FOR ELACESTRANT (ORSERDU), 2024 75
5.5.2 QUALITATIVE PRICING INSIGHTS FOR UPCOMING NOVEL TARGETED PROTEIN DEGRADERS 75
5.6 REIMBURSEMENT SCENARIO FOR ELACESTRANT (ORSERDU) 76
5.6.1 US 76
5.6.2 EUROPE 76
5.7 VALUE CHAIN ANALYSIS 77
5.8 ECOSYSTEM ANALYSIS 78
5.9 PATENT ANALYSIS 80
5.10 PIPELINE ANALYSIS 83
5.11 REGULATORY ANALYSIS 84
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 84
5.11.2 REGULATORY FRAMEWORK 86
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 88
5.13 PORTER’S FIVE FORCES ANALYSIS 89
5.13.1 THREAT OF NEW ENTRANTS 90
5.13.2 THREAT OF SUBSTITUTES 90
5.13.3 BARGAINING POWER OF SUPPLIERS 90
5.13.4 BARGAINING POWER OF BUYERS 90
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 91
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 91
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
5.14.2 KEY BUYING CRITERIA 93
5.15 INVESTMENT AND FUNDING SCENARIO 94
5.16 IMPACT OF AI/GEN AI ON NOVEL TARGETED PROTEIN DEGRADERS MARKET 95
5.17 IMPACT OF 2025 US TARIFFS ON NOVEL TARGETED PROTEIN DEGRADERS MARKET 96
5.17.1 INTRODUCTION 96
5.17.2 KEY TARIFF RATES 97
5.17.3 PRICE IMPACT ANALYSIS 97
5.17.4 IMPACT ON COUNTRY/REGION 97
5.17.4.1 North America 97
5.17.4.1.1 US 97
5.17.4.2 Europe 98
5.17.4.3 Asia Pacific 98
5.17.5 IMPACT ON END-USE INDUSTRIES 98
6 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE 99
6.1 INTRODUCTION 100
6.2 MOLECULAR GLUE 100
6.2.1 MEZIGDOMIDE (CC-92480) 104
6.2.1.1 Stronger cereblon binding and deeper substrate degradation to spur growth 104
6.2.2 IBERDOMIDE (CC-220) 107
6.2.2.1 Rising incidence of autoimmune diseases and cancer to boost market 107
6.3 SERDS 110
6.3.1 ELACESTRANT 113
6.3.1.1 Increasing approvals to contribute to growth 113
6.3.2 GIREDESTRANT (GDC9545) 116
6.3.2.1 Growing prevalence of breast cancer to drive market 116
6.3.3 CAMIZESTRANT (AZD9833) 119
6.3.3.1 High potency and strong receptor degradation to bolster growth 119
6.4 PROTAC 122
6.4.1 VEPDEGESTRANT (ARV-471) 126
6.4.1.1 Reliable systemic exposure and enhanced tumor targeting to support growth 126
6.4.2 LUXDEGALUTAMIDE 129
6.4.2.1 Favorable safety profile and early signals of efficacy to stimulate growth 129
6.4.3 BGB-16673 132
6.4.3.1 Higher efficacy and preference for oral formulation to aid growth 132
6.4.4 NX-5948 135
6.4.4.1 Advancements in next-gen oral BTK degraders targeting refractory B-cell malignancies to drive market 135
6.4.5 KT‑474 137
6.4.5.1 Rising importance in treating autoimmune and inflammatory diseases to aid growth 137
6.5 LDD/BIDAC 139
6.5.1 INCREASING USE OF LDD IN TUMOR-SPECIFIC DEGRADATION, HEMATOLOGIC CANCERS, AND IMMUNE MODULATION TO FUEL MARKET 139
6.6 LYTAC/ATAC 142
6.6.1 GROWING FOCUS ON CANCER IMMUNOTHERAPY TO DRIVE MARKET 142
6.7 AUTAC/ATTEC 144
6.7.1 GROWING USE OF AUTAC IN TREATING METABOLIC DISEASES AND RARE LYSOSOMAL STORAGE CONDITIONS TO BOOST MARKET 144
7 NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION 147
7.1 INTRODUCTION 148
7.2 ONCOLOGY 148
7.2.1 HIGH PREVALENCE OF MALIGNANCIES AND UNMET NEED FOR DURABLE THERAPIES TO PROMOTE GROWTH 148
7.3 INFLAMMATORY DISEASES 152
7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO AUGMENT GROWTH 152
7.4 OTHER DISEASES 154
8 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION 157
8.1 INTRODUCTION 158
8.2 ORAL FORMULATIONS 158
8.2.1 TABLETS 162
8.2.1.1 Manufacturing scalability, stability, and patient convenience to aid growth 162
8.2.2 CAPSULES 165
8.2.2.1 Higher flexibility, faster development timelines, and enhanced bioavailability to foster growth 165
8.3 INJECTIONS 168
8.3.1 ESSENTIAL ROLE IN RAPID AND TARGETED DELIVERY OF SYSTEMIC TARGETED PROTEIN DEGRADERS TO BOOST MARKET 168
9 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER 171
9.1 INTRODUCTION 172
9.2 HOSPITALS & SPECIALTY CLINICS 172
9.2.1 ROBUST INFRASTRUCTURE AND MULTI-DISCIPLINARY CARE TEAMS TO EXPEDITE GROWTH 172
9.3 LONG-TERM CARE FACILITIES 176
9.3.1 INCREASING FOCUS ON QUALITY OF LIFE TO CONTRIBUTE TO GROWTH 176
9.4 HOME CARE SETTINGS 179
9.4.1 GROWING FOCUS ON CHRONIC DISEASE MANAGEMENT TO DRIVE MARKET 179
10 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION 182
10.1 INTRODUCTION 183
10.2 NORTH AMERICA 183
10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA 184
10.2.2 US 189
10.2.2.1 Strong clinical pipeline and regulatory support to contribute to growth 189
10.2.3 CANADA 192
10.2.3.1 Favorable government initiatives to support growth 192
10.3 EUROPE 195
10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE 196
10.3.2 GERMANY 200
10.3.2.1 Strong industry-academia partnership to foster growth 200
10.3.3 UK 203
10.3.3.1 Presence of leading academic institutions and translational research hubs to aid growth 203
10.3.4 FRANCE 206
10.3.4.1 Presence of leading biotechnology and diagnostic companies to spur growth 206
10.3.5 ITALY 209
10.3.5.1 Increasing innovations in PROTAC technology to promote growth 209
10.3.6 SPAIN 213
10.3.6.1 Robust academic network to contribute to growth 213
10.3.7 REST OF EUROPE 215
10.4 ASIA PACIFIC 219
10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC 219
10.4.2 CHINA 224
10.4.2.1 Surge in clinical trial activities to spur growth 224
10.4.3 JAPAN 227
10.4.3.1 Large geriatric population to contribute to growth 227
10.4.4 INDIA 230
10.4.4.1 Expanding contract development and manufacturing organization infrastructure to fuel market 230
10.4.5 SOUTH KOREA 233
10.4.5.1 Rapidly expanding pharmaceutical manufacturing infrastructure to propel market 233
10.4.6 AUSTRALIA 236
10.4.6.1 Streamlined clinical trial environment to accelerate growth 236
10.4.7 REST OF ASIA PACIFIC 239
10.5 LATIN AMERICA 243
10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA 243
10.5.2 BRAZIL 247
10.5.2.1 Regulatory evolution supporting trial acceleration to drive market 247
10.5.3 MEXICO 250
10.5.3.1 Rising demand for novel therapeutics for chronic disease treatment to support growth 250
10.5.4 REST OF LATIN AMERICA 253
10.6 MIDDLE EAST & AFRICA 257
10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA 257
10.6.2 GCC COUNTRIES 261
10.6.2.1 Saudi Arabia 265
10.6.2.1.1 Growing focus on life sciences sector to boost market 265
10.6.2.2 UAE 268
10.6.2.2.1 Emerging biotechnology sector to intensify growth 268
10.6.2.3 REST OF GCC countries 271
10.6.3 REST OF MIDDLE EAST & AFRICA 274
11 COMPETITIVE LANDSCAPE 278
11.1 INTRODUCTION 278
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 278
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET 278
11.3 REVENUE ANALYSIS, 2028–2030 280
11.4 MARKET SHARE ANALYSIS, 2030 281
11.5 COMPANY VALUATION AND FINANCIAL METRICS 283
11.5.1 COMPANY VALUATION 283
11.5.2 FINANCIAL METRICS 283
11.6 BRAND/PRODUCT COMPARISON 284
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 285
11.7.1 STARS 285
11.7.2 EMERGING LEADERS 285
11.7.3 PERVASIVE PLAYERS 285
11.7.4 PARTICIPANTS 285
11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 287
11.7.5.1 Company footprint 287
11.7.5.2 Region footprint 288
11.7.5.3 Degrader type footprint 289
11.7.5.4 Therapeutic indication footprint 290
11.7.5.5 Formulation footprint 291
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 292
11.8.1 PROGRESSIVE COMPANIES 292
11.8.2 RESPONSIVE COMPANIES 292
11.8.3 DYNAMIC COMPANIES 292
11.8.4 STARTING BLOCKS 292
11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 294
11.8.5.1 Detailed list of key startups/SMEs 294
11.8.5.2 Competitive benchmarking of key startups/SMEs 295
11.9 COMPETITIVE SCENARIO 296
11.9.1 PRODUCT LAUNCHES AND APPROVALS 296
11.9.2 DEALS 297
11.9.3 EXPANSIONS 298
12 COMPANY PROFILES 299
12.1 KEY PLAYERS 299
12.1.1 BRYSTOL-MYERS SQUIBB COMPANY 299
12.1.1.1 Business overview 299
12.1.1.2 Products offered 300
12.1.1.3 Recent developments 301
12.1.1.3.1 Deals 301
12.1.1.3.2 Expansions 302
12.1.1.4 MnM view 302
12.1.1.4.1 Key strengths 302
12.1.1.4.2 Strategic choices 302
12.1.1.4.3 Weaknesses and competitive threats 302
12.1.2 THE MENARINI GROUP 303
12.1.2.1 Business overview 303
12.1.2.2 Products offered 304
12.1.2.3 Recent developments 305
12.1.2.3.1 Product launches and approvals 305
12.1.2.4 MnM view 305
12.1.2.4.1 Key strengths 305
12.1.2.4.2 Strategic choices 305
12.1.2.4.3 Weaknesses and competitive threats 306
12.1.3 ARVINAS 307
12.1.3.1 Business overview 307
12.1.3.2 Products offered 308
12.1.3.3 Recent developments 308
12.1.3.3.1 Deals 308
12.1.3.4 MnM view 308
12.1.3.4.1 Key strengths 308
12.1.3.4.2 Strategic choices 309
12.1.3.4.3 Weaknesses and competitive threats 309
12.1.4 BEONE MEDICINES 310
12.1.4.1 Business overview 310
12.1.4.2 Products offered 311
12.1.4.3 Recent developments 311
12.1.4.3.1 Deals 311
12.1.5 NURIX THERAPEUTICS, INC. 312
12.1.5.1 Business overview 312
12.1.5.2 Products offered 313
12.1.5.3 Recent developments 313
12.1.5.3.1 Deals 313
12.1.6 KYMERA THERAPEUTICS, INC. 314
12.1.6.1 Business overview 314
12.1.6.2 Products offered 315
12.1.6.3 Recent developments 315
12.1.6.3.1 Deals 315
12.1.7 C4 THERAPEUTICS, INC. 316
12.1.7.1 Business overview 316
12.1.7.2 Products offered 317
12.1.7.3 Recent developments 317
12.1.7.3.1 Deals 317
12.1.8 ASTRAZENECA 318
12.1.8.1 Business overview 318
12.1.8.2 Products offered 319
12.1.8.3 Recent developments 320
12.1.8.3.1 Deals 320
12.1.8.3.2 Expansions 320
12.1.9 F. HOFFMANN-LA ROCHE LTD 321
12.1.9.1 Business overview 321
12.1.9.2 Products offered 322
12.1.9.3 Recent developments 323
12.1.9.3.1 Deals 323
12.1.10 BAYER AG 324
12.1.10.1 Business overview 324
12.1.10.2 Products offered 325
12.1.10.3 Recent developments 326
12.1.10.3.1 Deals 326
12.1.11 CAPTOR THERAPEUTICS 327
12.1.11.1 Business overview 327
12.1.11.2 Products offered 327
12.1.11.3 Recent developments 328
12.1.11.3.1 Deals 328
12.1.12 RANOK THERAPEUTICS CO. LTD. 329
12.1.12.1 Business overview 329
12.1.12.2 Products offered 329
12.1.12.3 Recent developments 329
12.1.12.3.1 Product launches and approvals 329
12.1.13 PFIZER INC. 330
12.1.13.1 Business overview 330
12.1.13.2 Products offered 331
12.1.13.3 Recent developments 332
12.1.13.3.1 Product launches and approvals 332
12.1.14 NOVARTIS AG 333
12.1.14.1 Business overview 333
12.1.14.2 Products offered 334
12.1.14.3 Recent developments 335
12.1.14.3.1 Deals 335
12.1.15 FOGHORN THERAPEUTICS 336
12.1.15.1 Business overview 336
12.1.15.2 Products offered 337
12.1.15.3 Recent developments 337
12.1.15.3.1 Deals 337
12.2 OTHER PLAYERS 338
12.2.1 MONTE ROSA THERAPEUTICS 338
12.2.2 BIOTHERYX, INC. 339
12.2.3 CULLGEN 340
12.2.4 NEOMORPH 340
12.2.5 LYCIA THERAPEUTICS 341
12.2.6 PHOTYS THERAPEUTICS 341
12.2.7 PLEXIUM, INC. 342
12.2.8 SEED THERAPEUTICS, INC. 343
12.2.9 AVILAR THERAPEUTICS, INC. 344
12.2.10 AUTOMERA 344
13 APPENDIX 345
13.1 DISCUSSION GUIDE 345
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 349
13.3 CUSTOMIZATION OPTIONS 351
13.4 RELATED REPORTS 352
13.5 AUTHOR DETAILS 353
LIST OF TABLES
TABLE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INCLUSIONS AND EXCLUSIONS 38
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 50
TABLE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RISK ANALYSIS 52
TABLE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT ANALYSIS
OF MARKET DYNAMICS 64
TABLE 5 KEY STRATEGIC PARTNERSHIPS IN NOVEL TARGETED PROTEINS MARKET 66
TABLE 6 REIMBURSEMENT SCENARIO IN EUROPEAN COUNTRIES 76
TABLE 7 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ROLE OF
COMPANIES IN ECOSYSTEM 79
TABLE 8 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2014–2024 80
TABLE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET: LIST OF PATENTS, 2022–2024 82
TABLE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PRODUCTS IN CLINICAL PIPELINE, 2025–2028 83
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGULATORY SCENARIO 86
TABLE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 88
TABLE 17 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
PORTER’S FIVE FORCES ANALYSIS 89
TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY DEGRADER TYPE (%) 92
TABLE 19 KEY BUYING CRITERIA, BY END USER 93
TABLE 20 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE,
2023–2035 (USD MILLION) 100
TABLE 21 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE,
BY TYPE, 2023–2035 (USD MILLION) 101
TABLE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE,
BY REGION, 2023–2035 (USD MILLION) 101
TABLE 23 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 101
TABLE 24 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 102
TABLE 25 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR
MOLECULAR GLUE, BY REGION, 2023–2035 (USD MILLION) 102
TABLE 26 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 103
TABLE 27 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY REGION, 2023–2035 (USD MILLION) 103
TABLE 28 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 103
TABLE 29 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE,
BY REGION, 2023–2035 (USD MILLION) 104
TABLE 30 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 104
TABLE 31 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 105
TABLE 32 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 105
TABLE 33 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106
TABLE 34 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MEZIGDOMIDE, BY REGION, 2023–2035 (USD MILLION) 106
TABLE 35 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106
TABLE 36 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE,
BY REGION, 2023–2035 (USD MILLION) 107
TABLE 37 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 107
TABLE 38 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE,
BY COUNTRY, 2023–2035 (USD MILLION) 108
TABLE 39 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108
TABLE 40 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2032 (USD MILLION) 109
TABLE 41 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR IBERDOMIDE, BY REGION, 2023–2035 (USD MILLION) 109
TABLE 42 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 109
TABLE 43 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE,
2023–2035 (USD MILLION) 110
TABLE 44 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY REGION,
2023–2035 (USD MILLION) 110
TABLE 45 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 46 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 47 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY COUNTRY, 2023–2035 (USD MILLION) 112
TABLE 48 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY COUNTRY, 2023–2035 (USD MILLION) 112
TABLE 49 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY REGION, 2023–2035 (USD MILLION) 112
TABLE 50 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 113
TABLE 51 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT,
BY REGION, 2023–2035(USD MILLION) 114
TABLE 52 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 114
TABLE 53 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT,
BY COUNTRY, 2023–2035(USD MILLION) 114
TABLE 54 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 115
TABLE 55 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 115
TABLE 56 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ELACESTRANT, BY REGION, 2023–2035(USD MILLION) 115
TABLE 57 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ELACESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 116
TABLE 58 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT,
BY REGION, 2023–2035 (USD MILLION) 116
TABLE 59 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 117
TABLE 60 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 117
TABLE 61 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 118
TABLE 62 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 118
TABLE 63 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR GIREDESTRANT, BY REGION, 2023–2035 (USD MILLION) 118
TABLE 64 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 119
TABLE 65 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT,
BY REGION, 2023–2035 (USD MILLION) 119
TABLE 66 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 120
TABLE 67 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 120
TABLE 68 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 121
TABLE 69 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 121
TABLE 70 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY REGION, 2023–2035 (USD MILLION) 121
TABLE 71 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 122
TABLE 72 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE,
2023–2035 (USD MILLION) 123
TABLE 73 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY REGION, 2023–2035 (USD MILLION) 123
TABLE 74 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 124
TABLE 75 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY COUNTRY, 2023–2035 (USD MILLION) 124
TABLE 76 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY COUNTRY, 2023–2035 (USD MILLION) 125
TABLE 77 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 125
TABLE 78 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY REGION, 2023–2035 (USD MILLION) 125
TABLE 79 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 126
TABLE 80 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT,
BY REGION, 2023–2035 (USD MILLION) 126
TABLE 81 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 82 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 83 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 84 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 85 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR VEPDEGESTRANT, BY REGION, 2023–2035 (USD MILLION) 128
TABLE 86 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 87 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE,
BY REGION, 2023–2035 (USD MILLION) 129
TABLE 88 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 129
TABLE 89 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 130
TABLE 90 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 130
TABLE 91 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 92 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LUXDEGALUTAMIDE, BY REGION, 2023–2035 (USD MILLION) 131
TABLE 93 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 94 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY REGION, 2023–2035 (USD MILLION) 132
TABLE 95 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 132
TABLE 96 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673,
BY COUNTRY, 2023–2035 (USD MILLION) 133
TABLE 97 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 133
TABLE 98 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 134
TABLE 99 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR BGB-16673, BY REGION, 2023–2035 (USD MILLION) 134
TABLE 100 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 134
TABLE 101 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY REGION, 2023–2035 (USD MILLION) 135
TABLE 102 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 135
TABLE 103 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948,
BY COUNTRY, 2023–2035 (USD MILLION) 136
TABLE 104 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948,
BY COUNTRY, 2023–2035 (USD MILLION) 136
TABLE 105 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 137
TABLE 106 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY REGION, 2023–2035 (USD MILLION) 138
TABLE 107 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY COUNTRY, 2023–2035 (USD MILLION) 138
TABLE 108 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474,
BY COUNTRY, 2023–2035 (USD MILLION) 138
TABLE 109 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474,
BY COUNTRY, 2023–2035 (USD MILLION) 139
TABLE 110 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY REGION, 2023–2035 (USD MILLION) 140
TABLE 111 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 140
TABLE 112 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC,
BY COUNTRY, 2023–2035 (USD MILLION) 140
TABLE 113 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 141
TABLE 114 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 141
TABLE 115 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LDD/BIDAC, BY REGION, 2023–2035 (USD MILLION) 141
TABLE 116 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 142
TABLE 117 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC,
BY REGION, 2023–2035 (USD MILLION) 143
TABLE 118 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LYTAC/ATAC, BY COUNTRY, 2023–2035 (USD MILLION) 143
TABLE 119 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC,
BY COUNTRY, 2023–2035 (USD MILLION) 143
TABLE 120 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023–2035 (USD MILLION) 144
TABLE 121 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ATTEC, BY REGION, 2023–2035 (USD MILLION) 145
TABLE 122 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ ATTEC, BY COUNTRY, 2023–2035 (USD MILLION) 145
TABLE 123 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC,
BY COUNTRY, 2023–2035 (USD MILLION) 145
TABLE 124 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC, BY COUNTRY, 2023–2035 (USD MILLION) 146
TABLE 125 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 148
TABLE 126 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 149
TABLE 127 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 149
TABLE 128 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2028 (USD MILLION) 150
TABLE 129 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2028 (USD MILLION) 150
TABLE 130 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 131 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 151
TABLE 132 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 133 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2023–2035 (USD MILLION) 152
TABLE 134 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 153
TABLE 135 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2028 (USD MILLION) 153
TABLE 136 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 154
TABLE 137 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES,
BY REGION, 2023–2035 (USD MILLION) 155
TABLE 138 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR OTHER DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 155
TABLE 139 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER
DISEASES, BY COUNTRY, 2023–2028 (USD MILLION) 155
TABLE 140 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR OTHER DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 156
TABLE 141 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION,
2023–2035 (USD MILLION) 158
TABLE 142 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS,
BY TYPE, 2023–2035 (USD MILLION) 158
TABLE 143 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS,
BY REGION, 2023–2035 (USD MILLION) 159
TABLE 144 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 159
TABLE 145 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2028 (USD MILLION) 160
TABLE 146 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2028 (USD MILLION) 160
TABLE 147 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 161
TABLE 148 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY REGION, 2023–2035 (USD MILLION) 161
TABLE 149 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 161
TABLE 150 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY REGION, 2023–2035 (USD MILLION) 162
TABLE 151 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 162
TABLE 152 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS,
BY COUNTRY, 2023–2028 (USD MILLION) 163
TABLE 153 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS,
BY COUNTRY, 2023–2035 (USD MILLION) 163
TABLE 154 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 164
TABLE 155 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR TABLETS, BY REGION, 2023–2035 (USD MILLION) 164
TABLE 156 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 164
TABLE 157 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES,
BY REGION, 2023–2035 (USD MILLION) 165
TABLE 158 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 165
TABLE 159 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES,
BY COUNTRY, 2023–2028 (USD MILLION) 166
TABLE 160 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 166
TABLE 161 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 167
TABLE 162 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY REGION, 2023–2035 (USD MILLION) 167
TABLE 163 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 167
TABLE 164 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY REGION, 2023–2035 (USD MILLION) 168
TABLE 165 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023–2035 (USD MILLION) 169
TABLE 166 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS,
BY COUNTRY, 2023–2028 (USD MILLION) 169
TABLE 167 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023–2035 (USD MILLION) 170
TABLE 168 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 172
TABLE 169 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS &
SPECIALTY CLINICS, BY REGION, 2023–2035 (USD MILLION) 173
TABLE 170 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 173
TABLE 171 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2028 (USD MILLION) 174
TABLE 172 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2028 (USD MILLION) 174
TABLE 173 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 175
TABLE 174 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2035 (USD MILLION) 175
TABLE 175 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 175
TABLE 176 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2035 (USD MILLION) 176
TABLE 177 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 176
TABLE 178 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR
LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2028 (USD MILLION) 177
TABLE 179 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 177
TABLE 180 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 178
TABLE 181 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2035 (USD MILLION) 178
TABLE 182 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR
LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 178
TABLE 183 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS,
BY REGION, 2023–2035 (USD MILLION) 179
TABLE 184 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 179
TABLE 185 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2028 (USD MILLION) 180
TABLE 186 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 180
TABLE 187 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 181
TABLE 188 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR HOME CARE SETTINGS, BY REGION, 2023–2035 (USD MILLION) 181
TABLE 189 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 181
TABLE 190 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION,
2023–2035 (USD MILLION) 183
TABLE 191 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 184
TABLE 192 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY COUNTRY, 2023–2035 (USD MILLION) 186
TABLE 193 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 186
TABLE 194 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 186
TABLE 195 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 187
TABLE 196 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 187
TABLE 197 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 187
TABLE 198 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 188
TABLE 199 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 188
TABLE 200 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 188
TABLE 201 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 189
TABLE 202 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE,
BY TYPE, 2023–2035 (USD MILLION) 190
TABLE 203 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 190
TABLE 204 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 190
TABLE 205 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 191
TABLE 206 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION,
2023–2035 (USD MILLION) 191
TABLE 207 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 191
TABLE 208 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 192
TABLE 209 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 193
TABLE 210 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 193
TABLE 211 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 193
TABLE 212 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 194
TABLE 213 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 194
TABLE 214 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 194
TABLE 215 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 195
TABLE 216 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 195
TABLE 217 EUROPE: KEY MACROECONOMIC INDICATORS 196
TABLE 218 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY COUNTRY, 2023–2035 (USD MILLION) 197
TABLE 219 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 197
TABLE 220 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR
MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 198
TABLE 221 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 198
TABLE 222 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 198
TABLE 223 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 199
TABLE 224 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 199
TABLE 225 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR
ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 199
TABLE 226 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 200
TABLE 227 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 201
TABLE 228 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 201
TABLE 229 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 201
TABLE 230 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 202
TABLE 231 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 202
TABLE 232 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 202
TABLE 233 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 203
TABLE 234 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 203
TABLE 235 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 204
TABLE 236 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE,
BY TYPE, 2023–2035 (USD MILLION) 204
TABLE 237 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 204
TABLE 238 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 205
TABLE 239 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 205
TABLE 240 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION,
2023–2035 (USD MILLION) 205
TABLE 241 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 206
TABLE 242 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 206
TABLE 243 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 207
TABLE 244 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 207
TABLE 245 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 207
TABLE 246 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 208
TABLE 247 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 208
TABLE 248 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 208
TABLE 249 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 209
TABLE 250 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 209
TABLE 251 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 210
TABLE 252 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 210
TABLE 253 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 211
TABLE 254 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 211
TABLE 255 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 211
TABLE 256 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 212
TABLE 257 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 212
TABLE 258 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 212
TABLE 259 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 213
TABLE 260 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 213
TABLE 261 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 214
TABLE 262 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 214
TABLE 263 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 214
TABLE 264 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 215
TABLE 265 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 215
TABLE 266 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 215
TABLE 267 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 216
TABLE 268 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 216
TABLE 269 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 217
TABLE 270 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 217
TABLE 271 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 217
TABLE 272 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 218
TABLE 273 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 218
TABLE 274 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 218
TABLE 275 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 220
TABLE 276 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 221
TABLE 277 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 221
TABLE 278 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 222
TABLE 279 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 222
TABLE 280 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 222
TABLE 281 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 223
TABLE 282 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 223
TABLE 283 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 223
TABLE 284 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 224
TABLE 285 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 225
TABLE 286 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 225
TABLE 287 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 225
TABLE 288 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 226
TABLE 289 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 226
TABLE 290 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 226
TABLE 291 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 227
TABLE 292 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 227
TABLE 293 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 228
TABLE 294 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 228
TABLE 295 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 228
TABLE 296 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 229
TABLE 297 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 229
TABLE 298 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 229
TABLE 299 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 230
TABLE 300 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 230
TABLE 301 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 231
TABLE 302 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 231
TABLE 303 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 231
TABLE 304 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 232
TABLE 305 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 232
TABLE 306 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 232
TABLE 307 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 233
TABLE 308 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 233
TABLE 309 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 234
TABLE 310 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 234
TABLE 311 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 234
TABLE 312 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 235
TABLE 313 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 235
TABLE 314 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 235
TABLE 315 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 236
TABLE 316 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 236
TABLE 317 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 237
TABLE 318 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 237
TABLE 319 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 237
TABLE 320 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 238
TABLE 321 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 238
TABLE 322 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 238
TABLE 323 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 239
TABLE 324 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 239
TABLE 325 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 240
TABLE 326 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 240
TABLE 327 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 241
TABLE 328 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 241
TABLE 329 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 241
TABLE 330 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 242
TABLE 331 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 242
TABLE 332 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 242
TABLE 333 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 244
TABLE 334 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY COUNTRY, 2023–2035 (USD MILLION) 244
TABLE 335 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 245
TABLE 336 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 245
TABLE 337 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 245
TABLE 338 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 246
TABLE 339 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 246
TABLE 340 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 246
TABLE 341 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 247
TABLE 342 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 247
TABLE 343 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 248
TABLE 344 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 248
TABLE 345 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 248
TABLE 346 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 249
TABLE 347 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 249
TABLE 348 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 249
TABLE 349 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 250
TABLE 350 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 250
TABLE 351 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 251
TABLE 352 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 251
TABLE 353 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 252
TABLE 354 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 252
TABLE 355 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 252
TABLE 356 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 253
TABLE 357 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 253
TABLE 358 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 253
TABLE 359 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 254
TABLE 360 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 254
TABLE 361 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 255
TABLE 362 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 255
TABLE 363 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 255
TABLE 364 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 256
TABLE 365 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 256
TABLE 366 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 256
TABLE 367 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 258
TABLE 368 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY REGION, 2023–2035 (USD MILLION) 258
TABLE 369 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 259
TABLE 370 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 259
TABLE 371 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 259
TABLE 372 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 260
TABLE 373 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 260
TABLE 374 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 260
TABLE 375 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 261
TABLE 376 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 261
TABLE 377 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 262
TABLE 378 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 262
TABLE 379 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 262
TABLE 380 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 263
TABLE 381 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 263
TABLE 382 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 263
TABLE 383 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 264
TABLE 384 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 264
TABLE 385 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 264
TABLE 386 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 265
TABLE 387 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 265
TABLE 388 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 266
TABLE 389 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 266
TABLE 390 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 266
TABLE 391 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 267
TABLE 392 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 267
TABLE 393 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 267
TABLE 394 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 268
TABLE 395 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE,
BY TYPE, 2023–2035 (USD MILLION) 268
TABLE 396 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS,
BY TYPE, 2023–2035 (USD MILLION) 269
TABLE 397 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 269
TABLE 398 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 269
TABLE 399 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION,
2023–2035 (USD MILLION) 270
TABLE 400 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 270
TABLE 401 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2023–2035 (USD MILLION) 270
TABLE 402 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY DEGRADER TYPE, 2023–2035 (USD MILLION) 271
TABLE 403 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 271
TABLE 404 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 272
TABLE 405 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC,
BY TYPE, 2023–2035 (USD MILLION) 272
TABLE 406 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 272
TABLE 407 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY FORMULATION, 2023–2035 (USD MILLION) 273
TABLE 408 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET
FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 273
TABLE 409 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET,
BY END USER, 2023–2035 (USD MILLION) 273
TABLE 410 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 274
TABLE 411 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 275
TABLE 412 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 275
TABLE 413 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 275
TABLE 414 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 276
TABLE 415 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 276
TABLE 416 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 276
TABLE 417 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 277
TABLE 418 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2023–2025 278
TABLE 419 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGREE OF COMPETITION 282
TABLE 420 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGION FOOTPRINT 288
TABLE 421 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGRADER TYPE FOOTPRINT 289
TABLE 422 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
THERAPEUTIC INDICATION FOOTPRINT 290
TABLE 423 NOVEL TARGETED PROTEIN DEGRADERS MARKET: FORMULATION FOOTPRINT 291
TABLE 424 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
DETAILED LIST OF KEY STARTUPS/SMES 294
TABLE 425 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024 295
TABLE 426 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 296
TABLE 427 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEALS,
JANUARY 2022–AUGUST 2025 297
TABLE 428 NOVEL TARGETED PROTEIN DEGRADERS MARKET: EXPANSIONS,
JANUARY 2022– AUGUST 2025 298
TABLE 429 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 299
TABLE 430 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 300
TABLE 431 BRISTOL MYERS SQUIBB COMPANY: DEALS, JANUARY 2022–JULY 2025 301
TABLE 432 BRISTOL-MYERS SQUIBB COMPANY: EXPANSIONS, JANUARY 2022–JULY 2025 302
TABLE 433 THE MENARINI GROUP: COMPANY OVERVIEW 303
TABLE 434 THE MENARINI GROUP: PRODUCTS OFFERED 304
TABLE 435 THE MENARINI GROUP: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 305
TABLE 436 ARVINAS: COMPANY OVERVIEW 307
TABLE 437 ARVINAS: PRODUCTS OFFERED 308
TABLE 438 ARVINAS: DEALS, JANUARY 2022–JULY 2025 308
TABLE 439 BEONE MEDICINES: COMPANY OVERVIEW 310
TABLE 440 BEONE MEDICINES: PRODUCTS OFFERED 311
TABLE 441 BEONE MEDICINES: DEALS, JANUARY 2022–JULY 2025 311
TABLE 442 NURIX THERAPEUTICS, INC.: COMPANY OVERVIEW 312
TABLE 443 NURIX THERAPEUTICS, INC.: PRODUCTS OFFERED 313
TABLE 444 NURIX THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 313
TABLE 445 KYMERA THERAPEUTICS, INC.: COMPANY OVERVIEW 314
TABLE 446 KYMERA THERAPEUTICS, INC.: PRODUCTS OFFERED 315
TABLE 447 KYMERA THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 315
TABLE 448 C4 THERAPEUTICS, INC.: COMPANY OVERVIEW 316
TABLE 449 C4 THERAPEUTICS, INC.: PRODUCTS OFFERED 317
TABLE 450 C4 THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 317
TABLE 451 ASTRAZENECA: COMPANY OVERVIEW 318
TABLE 452 ASTRAZENECA: PRODUCTS OFFERED 319
TABLE 453 ASTRAZENECA: DEALS, JANUARY 2022–JULY 2025 320
TABLE 454 ASTRAZENECA: EXPANSIONS, JANUARY 2022–JULY 2025 320
TABLE 455 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 321
TABLE 456 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 322
TABLE 457 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–JULY 2025 323
TABLE 458 BAYER AG: COMPANY OVERVIEW 324
TABLE 459 BAYER AG: PRODUCTS OFFERED 325
TABLE 460 BAYER AG: DEALS, JANUARY 2022–JULY 2025 326
TABLE 461 CAPTOR THERAPEUTICS: COMPANY OVERVIEW 327
TABLE 462 CAPTOR THERAPEUTICS: PRODUCTS OFFERED 327
TABLE 463 CAPTOR THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 328
TABLE 464 RANOK THERAPEUTICS CO. LTD.: COMPANY OVERVIEW 329
TABLE 465 RANOK THERAPEUTICS CO. LTD.: PRODUCTS OFFERED 329
TABLE 466 RANOK THERAPEUTICS CO. LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 329
TABLE 467 PFIZER INC.: COMPANY OVERVIEW 330
TABLE 468 PFIZER INC.: PRODUCTS OFFERED 331
TABLE 469 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 332
TABLE 470 NOVARTIS AG: COMPANY OVERVIEW 333
TABLE 471 NOVARTIS AG: PRODUCTS OFFERED 334
TABLE 472 NOVARTIS AG: DEALS, JANUARY 2022–JULY 2025 335
TABLE 473 FOGHORN THERAPEUTICS: COMPANY OVERVIEW 336
TABLE 474 FOGHORN THERAPEUTICS: PRODUCTS OFFERED 337
TABLE 475 FOGHORN THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 337
TABLE 476 MONTE ROSA THERAPEUTICS: COMPANY OVERVIEW 338
TABLE 477 BIOTHERYX, INC.: COMPANY OVERVIEW 339
TABLE 478 CULLGEN: COMPANY OVERVIEW 340
TABLE 479 NEOMORPH: COMPANY OVERVIEW 340
TABLE 480 LYCIA THERAPEUTICS: COMPANY OVERVIEW 341
TABLE 481 PHOTYS THERAPEUTICS: COMPANY OVERVIEW 341
TABLE 482 PLEXIUM, INC.: COMPANY OVERVIEW 342
TABLE 483 SEED THERAPEUTICS, INC.: COMPANY OVERVIEW 343
TABLE 484 AVILAR THERAPEUTICS, INC.: COMPANY OVERVIEW 344
TABLE 485 AUTOMERA: COMPANY OVERVIEW 344
LIST OF FIGURES
FIGURE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET SEGMENTATION
AND REGIONAL SCOPE 37
FIGURE 2 NOVEL TARGETED PROTEIN DEGRADERS MARKET: YEARS CONSIDERED 38
FIGURE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RESEARCH DESIGN 40
FIGURE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY DATA FROM
SECONDARY SOURCES 42
FIGURE 5 NOVEL TARGETED PROTEIN DEGRADERS MARKET: BREAKDOWN OF
PRIMARY INTERVIEWS 43
FIGURE 6 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 44
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030 45
FIGURE 8 REVENUE SHARE ANALYSIS OF MENARINI GROUP, 2024 45
FIGURE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE VALIDATION
FROM PRIMARY SOURCES 47
FIGURE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: TOP-DOWN APPROACH 48
FIGURE 11 NOVEL TARGETED PROTEIN DEGRADERS MARKET: CAGR PROJECTIONS 49
FIGURE 12 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DATA TRIANGULATION 51
FIGURE 13 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE,
2030 VS. 2035 (USD MILLION) 55
FIGURE 14 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2030 VS. 2035 (USD MILLION) 56
FIGURE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION,
2030 VS. 2035 (USD MILLION) 56
FIGURE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER,
2030 VS. 2035 (USD MILLION) 57
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF NOVEL TARGETED PROTEIN DEGRADERS MARKET 58
FIGURE 18 INCREASING RESEARCH INVESTMENTS AND RISING DEMAND FOR TARGETED TREATMENT TO DRIVE MARKET 59
FIGURE 19 SERDS SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2030 60
FIGURE 20 AUSTRALIA TO HAVE HIGHEST GROWTH DURING FORECAST PERIOD 61
FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 62
FIGURE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
FIGURE 23 NEW REVENUE POCKETS FOR PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET 74
FIGURE 24 NOVEL TARGETED PROTEIN DEGRADERS MARKET: VALUE CHAIN ANALYSIS 77
FIGURE 25 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ECOSYSTEM ANALYSIS 79
FIGURE 26 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 81
FIGURE 27 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
PORTER’S FIVE FORCES ANALYSIS 89
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DEGRADER TYPE 91
FIGURE 29 KEY BUYING CRITERIA, BY END USER 93
FIGURE 30 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2024 94
FIGURE 31 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT OF AI/GEN AI 95
FIGURE 32 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT 185
FIGURE 33 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT 220
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION) 280
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NOVEL
TARGETED PROTEIN DEGRADERS MARKET, 2030 281
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 283
FIGURE 37 EV/EBITDA OF KEY VENDORS 283
FIGURE 38 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
BRAND/PRODUCT COMPARISON 284
FIGURE 39 NOVEL TARGETED PROTEIN DEGRADERS MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 286
FIGURE 40 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY FOOTPRINT 287
FIGURE 41 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 293
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2024) 300
FIGURE 43 THE MENARINI GROUP: COMPANY SNAPSHOT (2024) 304
FIGURE 44 ARVINAS: COMPANY SNAPSHOT (2024) 307
FIGURE 45 BEONE MEDICINES: COMPANY SNAPSHOT (2024) 310
FIGURE 46 NURIX THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 312
FIGURE 47 KYMERA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 314
FIGURE 48 C4 THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 316
FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2024) 319
FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 322
FIGURE 51 BAYER AG: COMPANY SNAPSHOT (2024) 325
FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024) 331
FIGURE 53 NOVARTIS AG: COMPANY SNAPSHOT (2024) 334
FIGURE 54 FORGHORN THERAPEUTICS: COMPANY SNAPSHOT (2024) 336
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11